Registered title, quoted from ClinicalTrials.gov
Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study
An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. Led by Tangdu Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06663059, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 9
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (9 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically or cytologically confirmed esophageal squamous cell carcinoma.
Inclusion criterion 2
Locally advanced thoracic esophageal cancer assessed by CT/MRI/EUS, with clinical staging T1b-4aN+M0 or T2-4N0M0 (T2N0 patients must have high-risk factors such as lymphovascular invasion [LVI], tumor size ≥3 cm, or poor differentiation) (according to AJCC 8th edition).
Inclusion criterion 3
Female participants of childbearing potential must have a negative serum pregnancy test within 72 hours before starting the study drug and must use effective contraception (e.g., intrauterine device, contraceptive pills, or condoms) during the study and for at least 3 months after the last dose. Male participants with a fertile partner must be surgically sterilized or agree to use effective contraception during the study and for 3 months after the last dose.
Inclusion criterion 22
Immunosuppressive drugs or systemic steroids (doses > 10 mg/day of prednisone or equivalent) within 2 weeks prior to the first use of the study drug; inhaled or topical steroids and adrenal corticosteroids for non-active autoimmune diseases are allowed.
Exclusion criterion 8
Diagnosis of other malignant tumors within 5 years prior to the first use of the study drug, unless it is a low-risk malignancy (5-year survival rate > 90%), such as fully treated basal cell carcinoma, squamous cell skin cancer, or cervical carcinoma in situ.
Exclusion criterion 17
ECOG Performance Status 0-1.
Inclusion criterion 6
**Hematology** (no use of blood components, growth factors, white blood cell stimulants, platelet stimulants, or anemia-correcting drugs within 14 days before the first use of the study drug):
Inclusion criterion 11
Neutrophil count ≥1.5 × 10\^9/L
Inclusion criterion 12
Platelet count ≥100 × 10\^9/L
Inclusion criterion 13
Hemoglobin ≥90 g/L
Inclusion criterion 14
Total bilirubin ≤1.5 × ULN
Inclusion criterion 16
ALT ≤2.5 × ULN, AST ≤2.5 × ULN
Inclusion criterion 17
Serum creatinine ≤1.5 × ULN, or creatinine clearance ≥50 mL/min
Inclusion criterion 18
International Normalized Ratio (INR) ≤1.5 × ULN
Inclusion criterion 20
Activated Partial Thromboplastin Time (APTT) ≤1.5 × ULN
Inclusion criterion 21
Active pulmonary tuberculosis infection discovered by medical history or CT, or history of active pulmonary tuberculosis within the past year, or history of active pulmonary tuberculosis more than 1 year ago without formal treatment.
Exclusion criterion 15
History of immunodeficiency, including positive HIV test, or other acquired or congenital immunodeficiencies, or history of organ transplantation or allogeneic bone marrow transplantation.
Exclusion criterion 12
Active hepatitis B (HBV DNA ≥ 2000 IU/mL or 10\^4 copies/mL) or hepatitis C (positive HCV antibody, and HCV RNA above the lower limit of detection).
Exclusion criterion 16
Pregnant or breastfeeding women.
Exclusion criterion 18
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06663059, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Written informed consent must be signed, and the participant must voluntarily join the study.
- Histologically or cytologically confirmed esophageal squamous cell carcinoma.
- Locally advanced thoracic esophageal cancer assessed by CT/MRI/EUS, with clinical staging T1b-4aN+M0 or T2-4N0M0 (T2N0 patients must have high-risk factors such as lymphovascular invasion [LVI], tumor size ≥3 cm, or poor differentiation) (according to AJCC 8th edition).
- Expected to achieve R0 resection.
- Age between 18 and 75 years, regardless of gender.
- ECOG Performance Status 0-1.
- No prior treatment for esophageal cancer, including radiotherapy, chemotherapy, or surgery.
- Planning to undergo surgery after completing neoadjuvant therapy.
- No contraindications for surgery.
- Normal major organ functions, including:
- **Hematology** (no use of blood components, growth factors, white blood cell stimulants, platelet stimulants, or anemia-correcting drugs within 14 days before the first use of the study drug):
- Neutrophil count ≥1.5 × 10\^9/L
- Platelet count ≥100 × 10\^9/L
- Hemoglobin ≥90 g/L
- **Biochemistry**:
- Total bilirubin ≤1.5 × ULN
- ALT ≤2.5 × ULN, AST ≤2.5 × ULN
- Serum creatinine ≤1.5 × ULN, or creatinine clearance ≥50 mL/min
- **Coagulation**:
- International Normalized Ratio (INR) ≤1.5 × ULN
- Activated Partial Thromboplastin Time (APTT) ≤1.5 × ULN
- Female participants of childbearing potential must have a negative serum pregnancy test within 72 hours before starting the study drug and must use effective contraception (e.g., intrauterine device, contraceptive pills, or condoms) during the study and for at least 3 months after the last dose. Male participants with a fertile partner must be surgically sterilized or agree to use effective contraception during the study and for 3 months after the last dose.
- Good compliance with the study and cooperation with follow-up.
Exclusion Criteria:
- Tumor clearly invading adjacent organs (e.g., major arteries or trachea).
- Supraclavicular lymph node metastasis.
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
- Poor nutritional status, BMI < 18.5 kg/m²; if corrected with symptomatic nutritional support before randomization, may be considered for inclusion after assessment by the principal investigator.
- History of allergy to monoclonal antibodies, Adebrelimab or its components, paclitaxel, cisplatin, or other platinum-based drugs.
- Previous or current treatment with:
- Any tumor-directed radiotherapy, chemotherapy, or other anti-tumor drugs.
- Immunosuppressive drugs or systemic steroids (doses > 10 mg/day of prednisone or equivalent) within 2 weeks prior to the first use of the study drug; inhaled or topical steroids and adrenal corticosteroids for non-active autoimmune diseases are allowed.
- Live attenuated vaccines within 4 weeks prior to the first use of the study drug.
- Major surgery or severe trauma within 4 weeks prior to the first use of the study drug.
- Active autoimmune diseases or a history of autoimmune diseases, including but not limited to: interstitial pneumonia, colitis, hepatitis, pituitaryitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (considered if on hormone replacement therapy); psoriasis or childhood asthma/allergy in complete remission without intervention can be considered, but those requiring bronchodilators for medical intervention cannot be included.
- History of immunodeficiency, including positive HIV test, or other acquired or congenital immunodeficiencies, or history of organ transplantation or allogeneic bone marrow transplantation.
- Poorly controlled cardiac symptoms or diseases, including but not limited to: (1) NYHA Class II or higher heart failure, (2) unstable angina, (3) myocardial infarction within 1 year, (4) clinically significant supraventricular or ventricular arrhythmias not controlled or poorly controlled after clinical intervention.
- Severe infection (CTCAE > 2) within 4 weeks prior to the first use of the study drug, such as severe pneumonia, bacteremia, or infection complications requiring hospitalization; active pulmonary inflammation on baseline chest imaging, symptoms and signs of infection within 14 days prior to the first use of the study drug, or need for antibiotic treatment, except for prophylactic use.
- Active pulmonary tuberculosis infection discovered by medical history or CT, or history of active pulmonary tuberculosis within the past year, or history of active pulmonary tuberculosis more than 1 year ago without formal treatment.
- Active hepatitis B (HBV DNA ≥ 2000 IU/mL or 10\^4 copies/mL) or hepatitis C (positive HCV antibody, and HCV RNA above the lower limit of detection).
- Diagnosis of other malignant tumors within 5 years prior to the first use of the study drug, unless it is a low-risk malignancy (5-year survival rate > 90%), such as fully treated basal cell carcinoma, squamous cell skin cancer, or cervical carcinoma in situ.
- Pregnant or breastfeeding women.
- Any condition that, in the investigator's judgment, may lead to withdrawal from the study, such as other serious illnesses (including mental illnesses) requiring concurrent treatment, alcohol or drug abuse, family or social factors that may affect the participant's safety or compliance.
Quoted from ClinicalTrials.gov, NCT06663059, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06663059, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.